Skip to main content
Artificial Organs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, Japan - Size and Forecast 2024-2028

Artificial Organs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, Japan - Size and Forecast 2024-2028

Published: Jun 2024 175 Pages SKU: IRTNTR44011

Market Overview at a Glance

$14.85 B
Market Opportunity
9.49%
CAGR
8.79
YoY growth 2023-2024(%)

Artificial Organs Market Size 2024-2028

The artificial organs market size is forecast to increase by USD 14.85 billion, at a CAGR of 9.49% between 2023 and 2028.

  • The market is witnessing significant growth, driven by the increasing prevalence of chronic disorders and the emergence of total artificial hearts (TAH). Chronic disorders, such as end-stage renal disease, diabetes, and cardiovascular diseases, continue to rise globally, fueling the demand for artificial organs. TAH, a promising development, offers a potential solution for patients with heart failure, providing an alternative to heart transplants. However, the high cost of artificial organs remains a significant challenge, limiting their accessibility to a large population. Companies in this market must focus on cost reduction strategies, such as economies of scale and technological advancements, to address this challenge and expand their reach.
  • Additionally, collaborations and partnerships with healthcare providers and insurance companies can help offset the financial burden for patients and increase market penetration. In summary, the market presents significant growth opportunities for companies that can effectively navigate the challenges and capitalize on the increasing demand for these life-saving solutions.

What will be the Size of the Artificial Organs Market during the forecast period?

Artificial Organs Market Size

Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.  
Request Free Sample

The market continues to evolve, driven by advancements in bioreactor design, cellular therapies, and organ transplantation. Bioreactor systems, which provide optimal conditions for cell growth and tissue development, are a key focus. Perfusion bioreactors, in particular, enable the continuous culture of cells and tissues, advancing the field of regenerative medicine. Biocompatibility testing, mechanical properties, and in vitro testing are essential components of bioreactor development. Biomaterial compatibility and biocompatibility assays play a crucial role in ensuring the success of these systems. Mechanical properties must mimic those of natural organs, while in vitro testing provides valuable insights into the performance of bioreactors.

Artificial heart valves, bioartificial liver, and bioartificial pancreas are just a few applications of these technologies. Stem cell differentiation and scaffold design are critical areas of research, with the goal of creating functional, long-term stable organs. Regulatory approval and clinical trials are ongoing processes that ensure the safety and efficacy of these innovations. Bioprinting resolution and cell seeding methods are advancing rapidly, enabling the creation of complex tissue structures. In vivo testing and implant integration are the next frontiers, with drug delivery systems and surgical techniques playing essential roles in the successful implementation of these technologies.

Organ perfusion and 3D bioprinting are further expanding the potential applications of artificial organs. Tissue engineering and bioartificial organs are revolutionizing the medical landscape, offering new solutions for organ failure and chronic diseases. The continuous dynamism of this market is fueled by the ongoing research and development efforts in these areas.

How is this Artificial Organs Industry segmented?

The artificial organs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

  • Usage
    • Implantable
    • Extracorporeal
  • Product
    • Artificial heart
    • Artificial kidney
    • Cochlear implants
    • Artificial pancreas
  • Geography
    • North America
      • US
    • Europe
      • France
      • Germany
      • UK
    • APAC
      • Japan
    • Rest of World (ROW)

By Usage Insights

The implantable segment is estimated to witness significant growth during the forecast period.

The market is experiencing significant growth due to the increasing prevalence of organ failure and advancements in technology. With a limited supply of donor organs, there is a pressing need for alternatives, leading to the development of bioartificial organs such as bioartificial livers and pancreas. Bioreactor design and cellular therapies, including stem cell differentiation and scaffold design, are at the forefront of this innovation. Biocompatibility testing and mechanical properties assessment are crucial in ensuring the success of these advanced solutions. In vitro testing plays a vital role in evaluating the performance of artificial heart valves and perfusion bioreactors.

Regulatory approval and clinical trials are essential steps in bringing these technologies to market, with regenerative medicine and long-term stability being key considerations. Companies are investing in research and development to create more sophisticated solutions, such as drug delivery systems and surgical techniques for organ perfusion. For instance, Abbott's Aveir DR, the world's first dual-chamber leadless pacemaker system, received FDA approval in July 2023. The market is further propelled by advances in 3D bioprinting and tissue engineering, offering potential for organ-specific cell seeding methods and bioprinting resolution. These trends underscore the market's potential for continued growth and innovation.

Artificial Organs Market Size

Request Free Sample

The Implantable segment was valued at USD 11.85 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Artificial Organs Market Share by Geography

 Request Free Sample

The market in North America is experiencing substantial growth, with the United States and Canada leading the charge. Factors fueling this expansion include the rising adoption of technologically advanced devices, an increasing number of product launches, and a robust presence of industry players. Chronic diseases such as diabetes, cardiovascular diseases, and chronic kidney disease (CKD) are on the rise, further propelling market growth. For example, Tandem Diabetes Care Inc. Has introduced advanced insulin pumps, while bioreactor design and 3D bioprinting technologies are revolutionizing organ engineering. Biocompatibility testing, mechanical properties evaluation, and in vitro testing are crucial elements in ensuring the success of these innovative solutions.

As regenerative medicine advances, long-term stability, implant integration, and drug delivery systems are becoming increasingly important. Clinical trials and regulatory approval processes are ongoing, with a focus on improving organ perfusion and creating bioartificial livers, pancreas, and kidneys. In vivo testing and surgical techniques are also undergoing refinement to enhance the effectiveness of these bioartificial organs.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

The development of bioartificial organs presents numerous challenges that must be addressed to ensure their successful implementation in clinical settings. One of the major hurdles is the scale-up of bioreactor systems for organ production, which requires optimizing the design parameters to maintain the structural integrity and functionality of the tissue. Immunosuppressive drug regimens must also be optimized to minimize the risk of organ rejection, and 3D bioprinting of vascularized tissues offers a promising solution for creating complex structures with intricate vasculature. Biomaterial surface modification techniques are essential for enhancing the in-vivo biocompatibility of bioartificial organs. The evaluation of their biocompatibility using in-vivo models is crucial to assess their long-term stability and effectiveness. Bioartificial organ failure detection systems are being developed to monitor organ function and detect any anomalies in real-time. Decellularized matrices are being explored as scaffolds for organ regeneration, and cell seeding methods such as perfusion bioreactors are being optimized for bioartificial liver production. Tissue engineering approaches are being used to develop artificial heart valves, and regulatory pathways for bioartificial organs are being established to ensure market adherence to research report standards. Bioartificial pancreas cell encapsulation and immunomodulatory strategies are being investigated to minimize the risk of organ rejection. Long-term stability analysis is crucial to ensure the durability of bioartificial organs, and cost-effectiveness is a significant consideration for their widespread adoption. The design of perfusion bioreactor systems and bioreactor control and monitoring systems are essential components of the production process. Bioartificial kidney transplantation protocols are being developed to minimize the risks associated with traditional kidney transplants. The optimization of immunosuppressive drug regimens and the development of immunomodulatory strategies are critical to ensuring the success of these procedures. The market is expected to grow significantly in the coming years, and continued research and innovation are necessary to address the challenges and bring these life-saving technologies to patients.

What are the key market drivers leading to the rise in the adoption of Artificial Organs Industry?

  • The rising prevalence of chronic disorders serves as the primary market driver, significantly expanding the market scope. 
  • The demand for artificial organs is projected to grow significantly due to the increasing prevalence of chronic diseases, such as diabetes, kidney diseases, hearing disorders, and cardiovascular diseases (CVDs), as well as the aging population. Unhealthy lifestyles leading to conditions like hypertension, obesity, abnormal cholesterol, and diabetes are major contributors to the rise in cardiac disorders, particularly among individuals aged 60 and above. According to the CDC, approximately 795,000 Americans experience a stroke each year. Advancements in technology, such as device miniaturization and bioreactor design, are driving innovation in the field of artificial organs. Bioreactor systems, which provide an artificial environment for the growth and maintenance of cells, are increasingly being used in cellular therapies.
  • Biocompatibility testing and ensuring biomaterial compatibility are crucial aspects of developing artificial organs with optimal mechanical properties. These advancements are expected to address the challenges associated with organ transplantation and organ donation, providing viable solutions for those in need.

What are the market trends shaping the Artificial Organs Industry?

  • The trend in the market is leaning towards the emergence of TAH technology. This advanced innovation is gaining significant attention and recognition.
  • Artificial hearts have gained significant attention as a potential solution for patients with end-stage biventricular heart failure who are awaiting orthotopic heart transplantation. Due to the increasing incidence of cardiovascular diseases, the number of patients in need of a heart transplant exceeds the available donor hearts. Consequently, there is a growing demand for mechanical circulatory support devices, such as total artificial hearts (TAH), which can serve as a bridge to transplantation (BTT) for patients at imminent risk of death. Companies like SynCardia offer TAH with advanced features, such as a pulsatile system capable of handling flows greater than 9 L/min.
  • This technology is designed to provide adequate circulatory support until a donor heart becomes available. SynCardia's TAH is pneumatically driven and approved for use as a BTT worldwide. In vitro testing plays a crucial role in the development of artificial organs, ensuring their biocompatibility and functionality. Biocompatibility assays and scaffold design are essential components of the in vitro testing process. Stem cell differentiation and the creation of bioartificial organs, such as bioartificial livers and pancreas, are also areas of active research. Extracorporeal support systems are being developed to provide temporary organ replacement and bridge the gap until a transplant can be performed.
  • These advancements offer hope for patients with end-stage organ failure, expanding the possibilities for life-saving treatments.

What challenges does the Artificial Organs Industry face during its growth?

  • The exorbitant costs associated with producing artificial organs represents a significant barrier to growth within the industry. 
  • Artificial organs, a crucial advancement in regenerative medicine, offer solutions for individuals suffering from organ failure. The creation of these organs involves intricate processes such as perfusion bioreactors, which maintain the viability of cells during growth. Bioprinting resolution and cell seeding methods are essential in building the organ structure, ensuring long-term stability. However, the production of artificial organs comes with substantial costs. The process involves the use of specialized biomaterials, time, and care, leading to high expenses. For instance, an artificial heart's total cost includes the surgical procedure, device and console, and ongoing medical surveillance, amounting to approximately USD 17,500 to USD 120,000 annually.
  • Navigating the regulatory approval process and clinical trials further adds to the costs. Despite these challenges, the potential benefits of artificial organs make the investment worthwhile for those in need. As the field advances, researchers continue to explore ways to optimize production methods and reduce costs without compromising quality.

Exclusive Customer Landscape

The artificial organs market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the artificial organs market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Artificial Organs Market Share by Geography

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, artificial organs market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

Abbott Laboratories - Artificial organs developed by this company incorporate the gut microbiome, an intricate ecosystem of microbes, including bacteria, fungi, and viruses, that naturally exist within US. 

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

  • Abbott Laboratories
  • Asahi Kasei Corp.
  • B.Braun SE
  • Baxter International Inc.
  • BioTelemetry Inc.
  • BIOTRONIK SE and Co. KG
  • BiVACOR Inc.
  • Boston Scientific Corp.
  • Cochlear Ltd.
  • F. Hoffmann La Roche Ltd.
  • Fresenius Medical Care AG and Co. KGaA
  • Insulet Corp.
  • MED EL Elektromedizinische Gerate GmbH
  • Medtronic Plc
  • Nihon Kohden Corp.
  • Nikkiso Co. Ltd.
  • Nipro Corp.
  • Sonova AG
  • SynCardia Systems LLC
  • Tandem Diabetes Care Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Development and News in Artificial Organs Market

  • In January 2024, Medtronic plc, a global healthcare solutions company, announced the U.S. Food and Drug Administration (FDA) approval of its new HeartMate 3 LVAD (Left Ventricular Assist Device) system. This advanced technology offers improved patient outcomes and extended battery life, making it a significant advancement in the market (Medtronic Press Release, 2024).
  • In March 2024, Thermo Fisher Scientific and Organovo Holdings, Inc., a leading 3D bioprinting company, entered into a strategic collaboration to develop functional human tissues for research and therapeutic applications. This partnership combines Thermo Fisher's expertise in cell culture and bioprocessing with Organovo's 3D bioprinting capabilities, marking a significant step forward in the development of artificial organs (Thermo Fisher Scientific Press Release, 2024).
  • In May 2024, German biotech company, Cytosurge AG, raised €25 million in a Series C funding round. This investment will support the commercialization of its organ-on-chip technology, which mimics the structure and function of human organs, enabling more accurate drug testing and toxicology studies (Cytosurge Press Release, 2024).
  • In April 2025, the European Commission approved the market authorization for the RenalGuard System, a novel, portable kidney protection device developed by Fresenius Medical Care. This device helps prevent kidney damage during cardiovascular procedures, expanding the company's product portfolio and increasing its presence in the market (Fresenius Medical Care Press Release, 2025).

Research Analyst Overview

  • The market encompasses innovative solutions for addressing organ failure, including drug eluting stents and surgical approaches. Advanced technologies, such as bioartificial hearts, are under development to improve patient outcomes. Failure analysis and decellularized matrix research are crucial for understanding cell signaling and perfusion technology in creating functional organs. Post-operative care, bioreactor optimization, and scaffold degradation are essential aspects of long-term efficacy.
  • Hybrid organs, tissue remodeling, and patient selection are key trends in the market. System integration, quality control, and device sterilization are crucial for ensuring performance monitoring and clinical outcomes. Microfluidic devices, bioprinting materials, and vascular network development are advancing the field. Immunological tolerance, bioartificial lung, complications management, and cell culture techniques are critical areas of research.

Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Artificial Organs Market insights. See full methodology.

Market Scope

Report Coverage

Details

Page number

175

Base year

2023

Historic period

 2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 9.49%

Market growth 2024-2028

USD 14854.5 million

Market structure

Fragmented

YoY growth 2023-2024(%)

8.79

Key countries

US, Germany, UK, France, and Japan

Competitive landscape

Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Request Free Sample

What are the Key Data Covered in this Artificial Organs Market Research and Growth Report?

  • CAGR of the Artificial Organs industry during the forecast period
  • Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
  • Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
  • Accurate predictions about upcoming growth and trends and changes in consumer behaviour
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market's competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the artificial organs market growth of industry companies

We can help! Our analysts can customize this artificial organs market research report to meet your requirements.

Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Executive Summary - Chart on Market Overview
    • Executive Summary - Data Table on Market Overview
    • Executive Summary - Chart on Global Market Characteristics
    • Executive Summary - Chart on Market by Geography
    • Executive Summary - Chart on Market Segmentation by Usage
    • Executive Summary - Chart on Market Segmentation by Product
    • Executive Summary - Chart on Incremental Growth
    • Executive Summary - Data Table on Incremental Growth
    • Executive Summary - Chart on Company Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Parent Market
    • Data Table on - Parent Market
  • 2.2 Market characteristics
    • Market characteristics analysis
  • 2.3 Value chain analysis
    • Value Chain Analysis

3 Market Sizing

  • 3.1 Market definition
    • Offerings of companies included in the market definition
  • 3.2 Market segment analysis
    • Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Chart on Global - Market size and forecast 2023-2028 ($ million)
      • Data Table on Global - Market size and forecast 2023-2028 ($ million)
      • Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global Artificial Organs Market 2018 - 2022
      • Historic Market Size - Data Table on Global Artificial Organs Market 2018 - 2022 ($ million)
    • 4.2 Usage segment analysis 2018 - 2022
      • Historic Market Size - Usage Segment 2018 - 2022 ($ million)
    • 4.3 Product segment analysis 2018 - 2022
      • Historic Market Size - Product Segment 2018 - 2022 ($ million)
    • 4.4 Geography segment analysis 2018 - 2022
      • Historic Market Size - Geography Segment 2018 - 2022 ($ million)
    • 4.5 Country segment analysis 2018 - 2022
      • Historic Market Size - Country Segment 2018 - 2022 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Bargaining power of buyers - Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Bargaining power of suppliers - Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Threat of new entrants - Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Threat of substitutes - Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Threat of rivalry - Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Usage

    • 6.1 Market segments
      • Chart on Usage - Market share 2023-2028 (%)
      • Data Table on Usage - Market share 2023-2028 (%)
    • 6.2 Comparison by Usage
      • Chart on Comparison by Usage
      • Data Table on Comparison by Usage
    • 6.3 Implantable - Market size and forecast 2023-2028
      • Chart on Implantable - Market size and forecast 2023-2028 ($ million)
      • Data Table on Implantable - Market size and forecast 2023-2028 ($ million)
      • Chart on Implantable - Year-over-year growth 2023-2028 (%)
      • Data Table on Implantable - Year-over-year growth 2023-2028 (%)
    • 6.4 Extracorporeal - Market size and forecast 2023-2028
      • Chart on Extracorporeal - Market size and forecast 2023-2028 ($ million)
      • Data Table on Extracorporeal - Market size and forecast 2023-2028 ($ million)
      • Chart on Extracorporeal - Year-over-year growth 2023-2028 (%)
      • Data Table on Extracorporeal - Year-over-year growth 2023-2028 (%)
    • 6.5 Market opportunity by Usage
      • Market opportunity by Usage ($ million)
      • Data Table on Market opportunity by Usage ($ million)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Chart on Product - Market share 2023-2028 (%)
      • Data Table on Product - Market share 2023-2028 (%)
    • 7.2 Comparison by Product
      • Chart on Comparison by Product
      • Data Table on Comparison by Product
    • 7.3 Artificial heart - Market size and forecast 2023-2028
      • Chart on Artificial heart - Market size and forecast 2023-2028 ($ million)
      • Data Table on Artificial heart - Market size and forecast 2023-2028 ($ million)
      • Chart on Artificial heart - Year-over-year growth 2023-2028 (%)
      • Data Table on Artificial heart - Year-over-year growth 2023-2028 (%)
    • 7.4 Artificial kidney - Market size and forecast 2023-2028
      • Chart on Artificial kidney - Market size and forecast 2023-2028 ($ million)
      • Data Table on Artificial kidney - Market size and forecast 2023-2028 ($ million)
      • Chart on Artificial kidney - Year-over-year growth 2023-2028 (%)
      • Data Table on Artificial kidney - Year-over-year growth 2023-2028 (%)
    • 7.5 Cochlear implants - Market size and forecast 2023-2028
      • Chart on Cochlear implants - Market size and forecast 2023-2028 ($ million)
      • Data Table on Cochlear implants - Market size and forecast 2023-2028 ($ million)
      • Chart on Cochlear implants - Year-over-year growth 2023-2028 (%)
      • Data Table on Cochlear implants - Year-over-year growth 2023-2028 (%)
    • 7.6 Artificial pancreas - Market size and forecast 2023-2028
      • Chart on Artificial pancreas - Market size and forecast 2023-2028 ($ million)
      • Data Table on Artificial pancreas - Market size and forecast 2023-2028 ($ million)
      • Chart on Artificial pancreas - Year-over-year growth 2023-2028 (%)
      • Data Table on Artificial pancreas - Year-over-year growth 2023-2028 (%)
    • 7.7 Market opportunity by Product
      • Market opportunity by Product ($ million)
      • Data Table on Market opportunity by Product ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Chart on Market share by geography 2023-2028 (%)
      • Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Chart on Geographic comparison
      • Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Chart on North America - Market size and forecast 2023-2028 ($ million)
      • Data Table on North America - Market size and forecast 2023-2028 ($ million)
      • Chart on North America - Year-over-year growth 2023-2028 (%)
      • Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Chart on Europe - Market size and forecast 2023-2028 ($ million)
      • Data Table on Europe - Market size and forecast 2023-2028 ($ million)
      • Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Chart on Asia - Market size and forecast 2023-2028 ($ million)
      • Data Table on Asia - Market size and forecast 2023-2028 ($ million)
      • Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Chart on US - Market size and forecast 2023-2028 ($ million)
      • Data Table on US - Market size and forecast 2023-2028 ($ million)
      • Chart on US - Year-over-year growth 2023-2028 (%)
      • Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Chart on Germany - Market size and forecast 2023-2028 ($ million)
      • Data Table on Germany - Market size and forecast 2023-2028 ($ million)
      • Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 UK - Market size and forecast 2023-2028
      • Chart on UK - Market size and forecast 2023-2028 ($ million)
      • Data Table on UK - Market size and forecast 2023-2028 ($ million)
      • Chart on UK - Year-over-year growth 2023-2028 (%)
      • Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.10 France - Market size and forecast 2023-2028
      • Chart on France - Market size and forecast 2023-2028 ($ million)
      • Data Table on France - Market size and forecast 2023-2028 ($ million)
      • Chart on France - Year-over-year growth 2023-2028 (%)
      • Data Table on France - Year-over-year growth 2023-2028 (%)
    • 9.11 Japan - Market size and forecast 2023-2028
      • Chart on Japan - Market size and forecast 2023-2028 ($ million)
      • Data Table on Japan - Market size and forecast 2023-2028 ($ million)
      • Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Market opportunity by geography ($ million)
      • Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Opportunity/Restraints

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market opportunities/restraints

          11 Competitive Landscape

          • 11.1 Overview
            • 11.2 Competitive Landscape
              • Overview on criticality of inputs and factors of differentiation
            • 11.3 Landscape disruption
              • Overview on factors of disruption
            • 11.4 Industry risks
              • Impact of key risks on business

            12 Competitive Analysis

            • 12.1 Companies profiled
              • Companies covered
            • 12.2 Market positioning of companies
              • Matrix on companies position and classification
            • 12.3 Abbott Laboratories
              • Abbott Laboratories - Overview
              • Abbott Laboratories - Business segments
              • Abbott Laboratories - Key news
              • Abbott Laboratories - Key offerings
              • Abbott Laboratories - Segment focus
            • 12.4 Asahi Kasei Corp.
              • Asahi Kasei Corp. - Overview
              • Asahi Kasei Corp. - Business segments
              • Asahi Kasei Corp. - Key news
              • Asahi Kasei Corp. - Key offerings
              • Asahi Kasei Corp. - Segment focus
            • 12.5 B.Braun SE
              • B.Braun SE - Overview
              • B.Braun SE - Business segments
              • B.Braun SE - Key news
              • B.Braun SE - Key offerings
              • B.Braun SE - Segment focus
            • 12.6 Baxter International Inc.
              • Baxter International Inc. - Overview
              • Baxter International Inc. - Business segments
              • Baxter International Inc. - Key news
              • Baxter International Inc. - Key offerings
              • Baxter International Inc. - Segment focus
            • 12.7 BioTelemetry Inc.
              • BioTelemetry Inc. - Overview
              • BioTelemetry Inc. - Product / Service
              • BioTelemetry Inc. - Key offerings
            • 12.8 BIOTRONIK SE and Co. KG
              • BIOTRONIK SE and Co. KG - Overview
              • BIOTRONIK SE and Co. KG - Product / Service
              • BIOTRONIK SE and Co. KG - Key offerings
            • 12.9 BiVACOR Inc.
              • BiVACOR Inc. - Overview
              • BiVACOR Inc. - Product / Service
              • BiVACOR Inc. - Key offerings
            • 12.10 Boston Scientific Corp.
              • Boston Scientific Corp. - Overview
              • Boston Scientific Corp. - Business segments
              • Boston Scientific Corp. - Key news
              • Boston Scientific Corp. - Key offerings
              • Boston Scientific Corp. - Segment focus
            • 12.11 Cochlear Ltd.
              • Cochlear Ltd. - Overview
              • Cochlear Ltd. - Business segments
              • Cochlear Ltd. - Key news
              • Cochlear Ltd. - Key offerings
              • Cochlear Ltd. - Segment focus
            • 12.12 F. Hoffmann La Roche Ltd.
              • F. Hoffmann La Roche Ltd. - Overview
              • F. Hoffmann La Roche Ltd. - Business segments
              • F. Hoffmann La Roche Ltd. - Key news
              • F. Hoffmann La Roche Ltd. - Key offerings
              • F. Hoffmann La Roche Ltd. - Segment focus
            • 12.13 Fresenius Medical Care AG and Co. KGaA
              • Fresenius Medical Care AG and Co. KGaA - Overview
              • Fresenius Medical Care AG and Co. KGaA - Business segments
              • Fresenius Medical Care AG and Co. KGaA - Key offerings
              • Fresenius Medical Care AG and Co. KGaA - Segment focus
            • 12.14 Insulet Corp.
              • Insulet Corp. - Overview
              • Insulet Corp. - Product / Service
              • Insulet Corp. - Key offerings
            • 12.15 MED EL Elektromedizinische Gerate GmbH
              • MED EL Elektromedizinische Gerate GmbH - Overview
              • MED EL Elektromedizinische Gerate GmbH - Product / Service
              • MED EL Elektromedizinische Gerate GmbH - Key news
              • MED EL Elektromedizinische Gerate GmbH - Key offerings
            • 12.16 Medtronic Plc
              • Medtronic Plc - Overview
              • Medtronic Plc - Business segments
              • Medtronic Plc - Key news
              • Medtronic Plc - Key offerings
              • Medtronic Plc - Segment focus
            • 12.17 Nipro Corp.
              • Nipro Corp. - Overview
              • Nipro Corp. - Business segments
              • Nipro Corp. - Key offerings
              • Nipro Corp. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Inclusions checklist
                • Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Currency conversion rates for US$
              • 13.4 Research methodology
                • Research methodology
              • 13.5 Data procurement
                • Information sources
              • 13.6 Data validation
                • Data validation
              • 13.7 Validation techniques employed for market sizing
                • Validation techniques employed for market sizing
              • 13.8 Data synthesis
                • Data synthesis
              • 360 degree market analysis
                • 360 degree market analysis
              • 13.10 List of abbreviations
                • List of abbreviations

              Research Methodology

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              Interested in this report?

              Get your sample now to see our research methodology and insights!

              Download Now

              Frequently Asked Questions

              Artificial Organs market growth will increase by $ 14854.5 mn during 2024-2028.

              The Artificial Organs market is expected to grow at a CAGR of 9.49% during 2024-2028.

              Artificial Organs market is segmented by Usage( Implantable, Extracorporeal, Cochlear implants, Artificial pancreas) Product( Artificial heart, Artificial kidney, Cochlear implants, Artificial pancreas, MEA)

              Abbott Laboratories, Asahi Kasei Corp., B.Braun SE, Baxter International Inc., BioTelemetry Inc., BIOTRONIK SE and Co. KG, BiVACOR Inc., Boston Scientific Corp., Cochlear Ltd., F. Hoffmann La Roche Ltd., Fresenius Medical Care AG and Co. KGaA, Insulet Corp., MED EL Elektromedizinische Gerate GmbH, Medtronic Plc, Nihon Kohden Corp., Nikkiso Co. Ltd., Nipro Corp., Sonova AG, SynCardia Systems LLC, Tandem Diabetes Care Inc. are a few of the key vendors in the Artificial Organs market.

              North America will register the highest growth rate of 46% among the other regions. Therefore, the Artificial Organs market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

              US, Germany, UK, France, Japan

              • Increasing prevalence of chronic disordersThe increase in the prevalence of diabetes is the driving factor this market.
              • chronic kidney diseases is the driving factor this market.
              • hearing disorders is the driving factor this market.
              • and cardiovascular diseases (CVDs) is the driving factor this market.
              • such as strokes and cardiac diseases is the driving factor this market.
              • and the rise in the aging population is likely to increase the demand for artificial organs. The increase in physical inactivity and unhealthy diets will result in high blood pressure is the driving factor this market.
              • high blood glucose is the driving factor this market.
              • and high lipids leading to hypertension is the driving factor this market.
              • obesity is the driving factor this market.
              • abnormal cholesterol is the driving factor this market.
              • and diabetes problems. These factors lead to cardiac disorders among people is the driving factor this market.
              • especially those aged 60 years and above. In recent years is the driving factor this market.
              • the incidence and prevalence of CVDs such as strokes is the driving factor this market.
              • myocardial infarction is the driving factor this market.
              • and CADs have increased. According to the CDC 2021 report is the driving factor this market.
              • about 795 is the driving factor this market.
              • 000 people in the US suffer a stroke each year. Furthermore is the driving factor this market.
              • an estimated 92.1 million US adults have at least one form of CVD. By 2030 is the driving factor this market.
              • 43.9% of the US adult population is projected to have some form of CVD. Globally is the driving factor this market.
              • 80% of CVD mortality takes place in low and middle-income countries and occurs almost equally in men and women. The rise in the incidence of cardiovascular diseases has led to an increase in demand for devices such as pacemakers and total artificial hearts.According to The World Bank Group is the driving factor this market.
              • about 9.8% of the global population in the age group 20-19 years were living with diabetes in 2021. Also is the driving factor this market.
              • according to the CDC 2023 report is the driving factor this market.
              • about 37 million US adults are living with diabetes. The report also states that in 2021 is the driving factor this market.
              • about 88 million people in the US had prediabetes. This data is indicative of the increased adoption of artificial pancreas device systems is the driving factor this market.
              • which are infusion pumps that can adjust insulin delivery to the tissue under the skin.The prevalence of end-stage renal disease (ESRD) is the driving factor this market.
              • also known as end-stage kidney disease or chronic kidney disease is the driving factor this market.
              • is growing at a significant rate globally. Worldwide is the driving factor this market.
              • 10%-15% of the population is affected by ESRD is the driving factor this market.
              • and every year is the driving factor this market.
              • millions of people die of the disease because of the lack of affordable treatment options. According to the National Institutes of Health (NIH) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is the driving factor this market.
              • more than 661 is the driving factor this market.
              • 000 people in the US have kidney failure is the driving factor this market.
              • of which 468 is the driving factor this market.
              • 000 individuals are on dialysis is the driving factor this market.
              • and roughly 193 is the driving factor this market.
              • 000 live with a functioning kidney transplant. The prevalence of CVD among people aged 66 years and above with chronic kidney disease (CKD) is 69.6% is the driving factor this market.
              • compared with 34.7% among those who do not have CKD. Cardiovascular risk factors are higher among those with CKD than those without CKD.The prevalence of hearing loss is significantly rising in both developed and developing countries. According to the NIH is the driving factor this market.
              • about two to three children out of every 1 is the driving factor this market.
              • 000 are born with significant hearing loss in one or both ears. Approximately 37 million (15%) US adults over 18 years of age have hearing problems. In the US is the driving factor this market.
              • one out of eight people aged 12 years and above has lost hearing ability in both ears. Around 15% of US adults (37.5 million) aged 18 years and above have hearing problems. The risk of hearing loss is high in the older population due to age-related changes in the inner ear. Approximately 35% of the global population aged 65 years and above is affected by disabling hearing loss. Such factors can increase the adoption of cochlear implants. Thus is the driving factor this market.
              • the increase in the prevalence of chronic diseases is the major factor that is expected to drive the growth of the global artificial organs market during the forecast period. is the driving factor this market.

              The Artificial Organs market vendors should focus on grabbing business opportunities from the Implantable segment as it accounted for the largest market share in the base year.